Biogen (NASDAQ:BIIB) is a significant-cap biotech that has witnessed significant volatility this year, with over 40% cost swings in both equally...
Biogen
Cambridge biotech Biogen has agreed to pay $22 million to resolve allegations levied by federal prosecutors that it illegally applied...
